PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.01
Negative D/E while AXSM shows 0.00. Joel Greenblatt would look for hidden assets and restructuring catalysts.
0.35
Net debt of 0.35 while AXSM shows zero net debt. Bruce Berkowitz would look for higher returns justifying the leverage.
No Data
No Data available this quarter, please select a different quarter.
0.33
Current ratio of 0.33 while AXSM has zero ratio. Bruce Berkowitz would examine if our working capital management provides advantages.
No Data
No Data available this quarter, please select a different quarter.